To systematically review the evidence regarding the efficacy of vaccines or immunostimulants in reducing the recurrence rate of urinary tract infections (UTIs).
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Objectives
To systematically review the evidence regarding the efficacy of vaccines or immunostimulants in reducing the recurrence rate of urinary tract infections (UTIs).
Materials and Methods
The Medical Literature Analysis and Retrieval System Online (MEDLINE), Excerpta Medica dataBASE (EMBASE), PubMed, Cochrane Library, World Health Organization (WHO) International Clinical Trials Registry Platform Search Portal, and conference abstracts were searched up to January 2018 for English-titled citations. Randomised placebo-controlled trials evaluating UTI recurrence rates in adult patients with recurrent UTIs treated with a vaccine were selected by two independent reviewers according to the Population, Interventions, Comparators, and Outcomes (PICO) criteria. Differences in recurrence rates in study populations for individual trials were calculated and pooled, and risk ratios (RRs) using random effects models were calculated. Risk of bias was assessed using the Cochrane Collaboration's tool and heterogeneity was assessed using chi-squared and I 2 testing. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to evaluate the quality of evidence (QOE) and summarise findings.
Results
In all, 599 records were identified, of which 10 studies were included. A total of 1537 patients were recruited and analysed, on whom data were presented. Three candidate vaccines were studied: Uro-Vaxom â (OM Pharma, Myerlin, Switzerland), Urovac â (Solco Basel Ltd, Basel, Switzerland), and ExPEC4V (GlycoVaxyn AG, Schlieren, Switzerland). At trial endpoint, the use of vaccines appeared to reduce UTI recurrence compared to placebo (RR 0.74, 95% confidence interval [CI] 0.67-0.81; low QOE). Uro-Vaxom showed the greatest reduction in UTI recurrence rate; the maximal effect was seen at 3 months compared with 6 months after initial treatment (RR 0.67, 95% CI 0.57-0.78; and RR 0.78, 95% CI 0.69-0.88, respectively; low QOE). Urovac may also reduce risk of UTI recurrence (RR 0.75, 95% CI 0.63-0.89; low QOE). ExPEC4V does not appear to reduce UTI recurrence compared to placebo at study endpoint (RR 0.82, 95% CI 0.62-1.10; low QOE). Substantial heterogeneity was observed across the included studies (chi-squared = 54.58; P < 0.001, I 2 = 84%).
Introduction
UTIs are amongst the commonest bacterial infections, with a worldwide prevalence of community-associated UTIs of 0.7%. They pose a significant burden of disease globally, accounting for a significant proportion of healthcare-associated infections; almost a quarter of such infections occur in developing countries, with 12.9% and 19.6% occurring in the USA and Europe, respectively [1] . Women are disproportionately affected, with 10% aged >18 years reporting at least one suspected UTI per year, of whom 20-40% experience recurrent infection [2, 3] . The treatment of UTIs has become increasingly hindered by growing antibiotic resistance. Resistance to trimethoprim, the first-line agent for uncomplicated lower UTIs in many parts of the UK, has been reported as >20%. Furthermore, resistance to co-trimoxazole, the most common first-line treatment worldwide, is also widespread, particularly in developing countries, where it has been reported as high as 64%. Isolation of resistant urinary isolates is often associated with previous exposure to antibiotics [4] . In light of the high prevalence and recurrence rates of UTIs and rising antibiotic resistance, a number of different preventative interventions have been investigated in recent years.
Vaccine Strategies
Vaccines for the prevention of recurrent UTIs have been an important focus of study, the main aim of which is, rather than to kill infectious pathogens, to protect the host against infection by priming the immune response to uropathogens. Proof of concept and attempts at developing vaccines preceded an understanding of the exact mechanism of action of such immunostimulants.
Different vaccines strategies have employed the use of extracts derived from a range of uropathogens. OM-89, also known as Uro-Vaxom â (Vifor Pharma Ltd, OM Pharma, Myerlin, Switzerland), was initially registered for the prevention of recurrent cystitis in Germany and Switzerland [5] . This bacterial extract consists of lyophilised bacterial lysates derived from 18 different strains of Escherichia coli frequently implicated in the pathogenesis of UTIs. Another vaccine preparation, Urovac â (Solco Basel Ltd, Basel, Switzerland), consists of 10 heat-killed uropathogenic species; this includes six serotypes of E. coli, Proteus vulgaris, Klebsiella pneumoniae, Morganella morganii, and Enterococcus faecalis, thereby incorporating a broader range of commonly implicated uropathogens and in theory providing broad protection. Moreover, one of the most recent developments is ExPEC4V (GlycoVaxyn AG, Schlieren, Switzerland), consisting of four bioconjugates containing O-antigens of E. coli serotypes O1A, O2, O6A, and O25B, a key immune evasion strategy utilised by the bacterium.
The objective of the present systematic review was to determine the efficacy and safety of immunostimulants in preventing UTI in adult patients with a history of recurrent UTIs.
Materials and Methods

Search Methods
We searched The Medical Literature Analysis and Retrieval System Online (MEDLINE), Excerpta Medica dataBASE (EMBASE), PubMed, Cochrane Library and the WHO International Clinical Trials Registry Platform Search Portal in January 2018 using search terms listed in Appendix 1. In addition, hand-searching of urology-related journals and proceedings of major urology conferences was undertaken.
Eligibility Criteria
Types of studies, participants, and interventions All randomised controlled trials (RCTs) assessing the effects of uropathogen-based candidate vaccines in comparison to placebo in human subjects were eligible. Adult (>18 years) male and female participants with a history of recurrent UTIs, as defined by the study authors, were eligible. Studies including the following populations or groups were excluded: indwelling catheter; pregnancy; lactation; complicated neurogenic urogenital disorders; severe cardiovascular disease, renal or hepatic insufficiency; immunosuppressed patients; and uncontrolled diabetes mellitus.
Outcome Measures
The primary outcome measure was the rate of UTI recurrence at trial endpoint. Secondary outcome measures on which data are presented are dysuria and adverse events (AEs).
Data Collection and Analysis
Two reviewers (N.A. and M.H.) screened all abstracts and full-text articles independently. Any disagreement was resolved by discussion. Data were collected on study characteristics (year of study, use of intervention, use of placebo, study setting, inclusion and exclusion criteria, followup duration, funding sources), patients' characteristics (gender, age, UTI recurrence), and outcome data. Outcome measures are as aforementioned. References were managed using Mendeley Desktop. The reference lists of other review articles and key studies were also reviewed to ensure that no relevant studies were missed. We used standard methods according to the Preferred Reporting Items for Systematic Reviews (PRISMA) tool. The study protocol is registered on the International prospective register of systematic reviews: PROSPERO (CRD42017070006).
Data Analysis
Data on our outcomes of interest from the included RCTs were combined by meta-analysis to provide pooled effect estimates. We performed the statistical analyses according to the guidelines contained in the Cochrane Handbook for Systematic Reviews of Interventions, version 5.1.0 [6] . For dichotomous outcomes, we used the Mantel-Haenszel method; for continuous outcomes, we used the inverse 
Assessment of Scientific Quality
We determined the overall quality of evidence (QOE) according to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, which took into account five criteria not only related to internal validity (risk of bias, inconsistency, imprecision, and publication bias) but also external validity such as directness of the results. Two authors (N.A. and M.H.) independently rated the QOE for each outcome as 'high', 'moderate', 'low' or 'very low'; discrepancies were resolved by consensus or if needed by arbitration with the third author (Y.P.). We presented a summary of the evidence for the main outcomes in a 'summary of findings' table. This was performed using GRADEpro GDT software.
Assessment of Risk of Bias
Risk of bias was assessed according to the Cochrane Collaboration's tool for assessing risk of bias [7] . Studies were assessed according to risk of selection, performance, detection, attrition, and reporting bias, and were graded as 'low', 'high', and 'unclear' risk as defined in the Cochrane Handbook for Systematic Reviews of Interventions, version 5.1.0.
Assessment of Heterogeneity
Heterogeneity of data was assessed using chi-squared testing and I 2 percentage.
Results
Description of Studies
Results of the Search
The study selection process is outlined in Appendices 2 and 3. We identified 599 records. After abstract and full-text screening, 589 records were excluded as they did not meet the eligibility criteria for this review. Characteristics of included studies are summarised in Table 1 [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] .
On this basis, 10 RCTs were included, with a total of 1780 participants. Across the trials, data were not presented on a total of 243 patients; this was due to reasons as listed in Table 2 [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] . Data were therefore presented on 1537 patients according to the specified outcome measures.
Study Design
The included studies consisted of parallel RCTs using active comparators vs placebo, a non-immunogenic component administered by the same route as in the intervention groups.
With the exception of four studies, all used two groups; candidate vaccine vs placebo/control group. The remaining studies used three groups, so as to measure the effects of different vaccine doses [8, 9] , and the effects of primary and secondary immunisations [10, 11] , as shown in Table 3 [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] . Of these, for the purposes of comparison with the other studies, the group receiving the longest duration, highest dose, and/or additional booster, were used for greater comparison with placebo. In addition, the studies using three groups were also compared to one another separately, to assess the importance of dose, treatment duration, and secondary immunisation in order to confer the greatest degree of protection against recurrent UTI.
Sample Sizes
All studies took place in the outpatient setting. The smallest study included 64 participants [12] and the largest 453 participants [13] . Six studies recruited >100 participants [9, [13] [14] [15] [16] [17] .
Source of Funding
As shown in Table 4 [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] , authors of five RCTs disclosed sources of funding for their work [8] [9] [10] [11] 13] . The authors of the remaining five RCTs did not disclose any sources of funding [12, [14] [15] [16] , of which one disclosed information regarding employment involvement of study authors with listed pharmaceutical companies [17] .
Outcomes
UTI Recurrence Rate
UTI recurrence rate at trial endpoint was determined for each of the included studies with results pooled and a metaanalysis performed. Subgroup analyses for each vaccine at different time points where applicable were also performed. Overall at trial endpoint, the use of vaccines appears to reduce UTI recurrence compared to placebo (risk ratio [RR] 0.74, 95%CI 0.67-0.81; low QOE) (Fig. 1) . Subgroup analysis at 3 and 6 months following Uro-Vaxom suggests that UTI recurrence is reduced compared to placebo with the greatest effect seen at 3 months (RR 0.67, 95%CI 0.57-0.78; low QOE) (Fig. 2 ) compared to 6 months (RR 0.78, 95%CI 0.69-0.88; low QOE) (Fig. 3 ).
All three RCTs studying Urovac used three study populations: two used vaccine with booster, without booster, and placebo [10, 11] ; whereas one used high-dose vaccine, low-dosevaccine, and placebo [8] . Data on UTI recurrence rate were presented for each group in two studies [10, 11] and in one study was presented collectively as vaccine vs placebo [8] .
Overall Urovac reduces the risk of UTI recurrence (RR 0.75, 95%CI 0.63-0.89; low QOE). This effect appears more pronounced in patients receiving vaccine with booster compared to those receiving vaccine alone (Fig. 4) .
A single RCT investigated ExPEC4V vs placebo on UTI recurrence [9] . The evidence from this trial suggests that ExPEC4V does not reduce UTI recurrence compared to placebo at study endpoint (RR 0.82, 95%CI 0.62-1.10; low QOE).
In accordance with the GRADE approach, the quality of evidence for the use of vaccines in the prevention of UTIs was rated 'low' (Table 5 ).
In the overall comparison of UTI recurrence rates reported at trial endpoint in each trial, data for 1495 patients are presented, as shown in Fig. 1 . This discrepancy is because of the use of three patient groups in the Urovac studies. Highdose and booster-immunisation groups were used in comparison with placebo, when compared overall with the other UTI vaccine RCTs. Of the three Urovac RCTs, one RCT presented efficacy data for treatment groups collectively [8] . The other two Urovac RCTs presented these separately, and so data for the patients receiving Urovac without booster immunisation were not presented in the overall comparison, but has been presented in subgroup analysis (Fig. 4) . 
UTI Symptoms
Five studies assessed the role of Uro-Vaxom in reducing UTI symptoms in the form of dysuria vs placebo [12] [13] [14] [15] [16] . Overall, Uro-Vaxom appears to result in a large reduction in UTI symptoms in the form of dysuria at 6-months follow-up (RR 0.41, 95%CI 0.27-0.61; low QOE) (Fig. 5) . None of the other included RCTs specifically reported on UTI symptom outcomes.
AEs
Five studies reported on the incidence of AEs. Four studies reported on the incidence of AEs in participants receiving Uro-Vaxom vs placebo [13, 14, 16, 17] . These found no difference between Uro-Vaxom and placebo (RR 1.00, 95% CI 0.91-1.10).
A single RCT reported on the incidence of AEs in participants receiving ExPEC4V vs placebo [9] . This showed no significant difference in the incidence of AEs in those receiving ExPEC4V with those receiving placebo (RR 1.22, 95% CI 0.94-1.58).
Overall, no difference was seen in the incidence of AEs between patients receiving vaccine and placebo (RR 1.03, 95% CI 0.95-1.13; low QOE; Fig. 6 ). None of the studies assessing Urovac and the remaining UroVaxom studies presented data on AEs.
AEs reported in patients receiving
Risk of Bias
Quality appraisal of the 10 included RCTs was performed using the Cochrane Collaboration's tool for assessing risk of bias, as shown in Fig. 7 [7] . In summary, methodology pertaining to patient recruitment and randomisation was unclear, suggesting possible risk of selection bias. Blinding of participants and personnel was satisfactory and blinding of outcome assessment was similarly acceptable in all but one case. Outcome measurement and reporting were deemed at high risk of bias where outcome data were not reported fully.
Discussion
In the present systematic review, we evaluated whether existing candidate vaccines were clinically effective in the prevention of recurrent UTIs. The pooled results of the RCTs suggest a possible role for vaccines and immunostimulants in the management of patients with recurrent UTIs, having found a reduced UTI recurrence rate at trial endpoints compared with placebo ( Fig. 1) . However, these results should be interpreted with caution due to the low quality of the included trials.
At this stage, a firm conclusion over the most effective vaccine for reducing the recurrence rate of UTIs cannot be reached. The heterogeneity of the definitions used for UTI, trial endpoints, eligibility criteria, and study protocols amongst the trials included in the review, together with the low QOE was a major limiting factor for reliable and accurate comparison.
As discussed, 10 RCTs were included that studied three candidate vaccines; six studied Uro-Vaxom; three studied Urovac; and one studied ExPEC4V. One paper, Wagenlehner et al., 2015 [17] , studied OM-89S, a vaccine using the same strains of E. coli as Uro-Vaxom (OM-89) but manufactured by a different process; a modified lytic procedure was employed with this vaccine. It is unclear whether this manufacturing process has any effect on the overall efficacy of the vaccine, but OM-89S is no longer being produced.
The comparison of the studies was limited by the nature of definition of UTIs, and the duration over which the interventions were assessed against placebo. Schulman et al. [16] defined recurrence of UTI as the presence of bacteriuria with ≥10 5 bacteria/mL; however, in the absence of symptoms, [12] No information on source of funding disclosed. Hopkins et al. 2007 [11] Study supported by National Institute of Health Grants DK30808, DK44378, and DK61574. Huttner et al. 2017 [9] GlycoVaxyn, Janssen Vaccines. Confirmation that funders of study had no role in data collection, data monitoring, safety monitoring, or data analysis. Magasi et al. 1994 [15] No information on source of funding disclosed. Schulman et al. 1993 [16] No information on source of funding disclosed. Tammen et al. 1990 [14] No information on source of funding disclosed. Uehling et al. 2003 [10] Study supported by National Institute of Health Grant DK30808 and Solco Basel Ltd, Basel, Switzerland. Uehling et al. 1997 [8] Study supported by Public Health Service Grant DK 30808 and Solco Basel Ltd, Basel, Switzerland. Wagenlehner et al. 2015 [17] No information on source of funding disclosed. Disclosure statement regarding employment and involvement of study authors with pharmaceutical companies. No direct involvement of said companies in study stated.
© 2018 The Authors BJU International © 2018 BJU International 759 this may be classed as asymptomatic bacteriuria as opposed to recurrence of UTI, as defined by Wagenlehner et al. [17] , who rather defined UTI as the presence of at least two clinical symptoms accompanied by bacteriuria with ≥10 3 bacteria/mL. Equally, Bauer et al. [13] provided a clear definition of acute UTI as the presence of bacteriuria of
≥10
3 bacteria/mL, with at least two of the three symptoms (dysuria, burning sensation of micturition, and urinary frequency) lasting for ≥2 days. Given the wide discrepancy of definition, it is difficult to comment on whether the data provided by these studies corresponds to the precisely identical clinical phenomenon that is UTI. This might in part be contributed to by the study populations used, as illustrated by the differences in inclusion and exclusion criteria. On a broader level, adult patients with a history of recurrent UTIs were included in all studies; however, the definition of recurrent UTI was not uniform across all studies. Schulman et al. [16] defined this as ≥2 episodes/year, with Frey et al. [12] going further as to specify these as symptomatic episodes, whereas other studies defined this as ≥3 episodes/year [8, 10, 11, 13] . Huttner et al. [9] provided two possible definitions, with two or more *The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). GRADE Working Group grades of evidence. High certainty: We are very confident that the true effect lies close to that of the estimate of the effect. Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect. Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. = 3.69, df = 4 (P = 0.45); l 2 = 0% Test for overall effect: Z = 4.42 (P < 0.001) P < 0.001 recurrences over 6 months, as also stated by Tammen et al. [14] ; or alternatively three or more over the past year [9, 15] . By contrast, Magasi et al. [15] provided no definition at all for what constituted a history of recurrent UTIs.
More contentious was the issue of exclusion criteria. Firstly, Frey et al. [12] did not state any exclusion criteria at all. While Frey et al. [12] stated the inclusion of adult patients with recurrent UTI, defining this as ≥2 episodes/year, and with acute UTI, defined as at least 10 4 /mL mid-stream urine (MSU), no other differentiators are stated; therefore, one cannot comment on whether these patients had urogenital tract abnormalities. All other studies specifically excluded patients with urogenital tract abnormalities. Furthermore, Huttner et al. [9] excluded patients with acute urinary tract disease or infection from the comparison of ExPEC4V with placebo.
An additional limitation of the existing RCTs is the lack of subgroup analysis, including no differentiation between male and female participants; whilst some trials specified female participants amongst inclusion criteria [9, 11, 13] , not all clarified this and appeared to include both male and female patients with recurrent UTIs. As the pathogenesis of UTIs affecting some men may be different to those of women, while most of the studies excluded patients with urogenital tract abnormalities [8, 10, 11, [13] [14] [15] [16] , this limited interpretation of the results. On the same level, the lack of differentiation of specific patient populations, such as those with neurogenic lower urinary tract dysfunction, would also affect interpretation of the results. Further studies specifically within the population of male patients experiencing recurrent UTIs and also with subgroup analyses for specific patient groups experiencing recurrent UTIs are therefore needed to analyse efficacy of vaccines in preventing UTIs in different patient groups.
Moreover, one of the most important prerequisites of a successful vaccine in order to prevent future re-infection is the establishment of immune memory, in order for a secondary immune response to be triggered upon confrontation of the immune system with the uropathogens included within the vaccine formulations. None of the Urovac papers were able to illustrate statistically significant differences in anti-E. coli antibody concentrations within urine, serum, and vaginal secretions; nevertheless, Hopkins et al. [11] concluded that Urovac has greater potential in the induction of an antibody response within the vagina and bladder mucosa than a parenteral vaccine. Not only did comparison with placebo not yield any results of statistical significance, but no study has compared vaccine efficacy of parenteral vs vaginal vaccines in terms of antibody induction.
With regards to the safety and incidence of AEs in patients receiving vaccine vs placebo, four of six Uro-Vaxom RCTs and the ExPEC4V RCT presented data on AEs. Reassuringly, no AEs resulting in hospitalisation or death were reported. Of the AEs reported by study participants, the tenacity of any causal link with either vaccine remains to be fully elucidated and indeed not all were deemed directly attributable to either treatment. As shown in Table 6 , a range of AEs were reported; however, not described in all cases in detail by the study authors. As in the case of Wagenlehner et al. [17] , serious AEs were noted; however, with no description provided. Also, the degree of variation of the incidence of AEs as reported by these studies is intriguingly vast, even with the same vaccine preparation; Wagenlehner et al. 2015 reported an incidence of AEs of 85.91% amongst participants receiving Uro-Vaxom, whereas that reported by Schulman et al. 1993 was 2.35% [16, 17] . This raises questions regarding the methods by which patients were assessed for AEs by study investigators, and how links were drawn between the symptoms with which the study participants presented and the treatments they received; there is the possibility that studies reporting high AE rates may have erroneously attributed idiosyncratic symptoms to the vaccine and likewise those reporting low AEs failed to attribute reactions to the vaccine. Indeed in some cases, a distinction was made between AEs reported and those deemed attributable to the vaccine by physicians [16, 17] ; it would be interesting to see how the investigators determined the possibility of direct • Headache (17% both groups)
• GI side-effects (15% both groups)* Serious AEs: Uro-Vaxom (n = 11), placebo (n = 4)* No hospitalisations due to study treatments. • Vertigo with visual disturbance (n = 1)
• Subcutaneous nodules (n = 1)ᵜ Placebo:
• Precipitated voiding (n = 1)ᵜ ⁰AEs deemed to have possible relationship to treatment AEs deemed to have unlikely relationship to treatment ᵜAEs deemed to have no relationship with treatment Tammen et al. 1990 [14] Uro-Vaxom Placebo 6.56 3.38 Uro-Vaxom:
• Pruritus (n = 1)
• Allergic reaction leading to withdrawal* (n = 1)
• Diarrhoea (n = 1)
• Headache with flushing (n = 1) Placebo:
• Nausea (n = 1)
• Erythema (n = 1) • 189 patients had AEs.
• 13 patients had serious AEs • 7 patients discontinued treatment Placebo:
• 198 patients had AEs • 15 patients had serious AEs association of certain AEs with vaccine, with no statistically significant difference in symptoms as experienced between vaccine and placebo groups, and while the exact intended therapeutic effect of such vaccines remains to be fully elucidated.
While RCTs on vaccines for the prevention for recurrent UTIs have only been completed for those discussed, other vaccine strategies are in the process of development and merit mention. MV140 (Uromune â ; Immunotek, Madrid, Spain) is a bacterial vaccine consisting of a mixture of selected strains of E. coli, K. pneumoniae, P. vulgaris, and E. faecalis, incorporated into a sublingual preparation. A retrospective observational study showed reduction in the mean number of infections and in total number of positive urine cultures in patients receiving MV140 compared with those receiving prophylactic antibiotics [18] . Similarly positive effects were observed in a retrospective cohort study, which reported significantly longer UTI-free period [19] . A recent study documented the first experience of MV140 in the UK in the treatment of women with recurrent UTIs, which found 78% of women receiving the vaccine to not experience UTI recurrence in the 12-month follow-up period [20] . At present, a multicentre RCT involving three treatment groups is in the process of recruitment, aiming to study the efficacy and safety of MV140 in women with recurrent UTIs; however, as no RCT has been performed using this vaccine to date, it has not been included in our present analysis and no recommendation can be made regarding its use.
Conclusions
There is some evidence for reduction of recurrence in patients affected by recurrent UTIs receiving vaccination; however, before any vaccines can be recommended for routine clinical use, further RCTs are required, using uniformity of definitions and large sample populations, using the vaccines evaluated in the present review and those currently in development.
As the purpose of vaccination is to induce immune memory to ensure lasting immunity, future trials should aim to also assess long-term vaccine efficacy with long-term follow-up. While the vaccines trialled to date have shown some efficacy according to clinical parameters, there is little evidence to date accounting for their immunogenicity. As antibody induction is key to adaptive immune responses to uropathogens, future trials should consider assessing for serum or urine antibody titres. 
